NCT00724958View on ClinicalTrials.gov

Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)

CompletedOBSERVATIONAL
Enrollment

348

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Infliximab

Not specified in the protocol.

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00724958 - Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED) | Biotech Hunter | Biotech Hunter